Suregraft 0.25 Tablet
Manufacturer
Hospimax Healthcare Pvt Ltd
Salt Composition
Everolimus (0.25mg)
Key Information
Short Description
Suregraft 0.25 Tablet is used for the prevention of organ rejection in transplant patients and in combination with other medicines to treat cancers of breast, pancreas, lungs, and kidney.
Dosage Form
Tablet
Introduction
Suregraft 0.25 Tablet is used for the prevention of organ rejection in transplant patients. It regulates the body's immune response, so the body can accept the new organ. It is also used in combination with other medicines to treat cancers of breast, pancreas, lungs, and kidney.
Directions for Use
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Suregraft 0.25 Tablet may be taken with or without food but it is better to take it at a fixed time.
How it works
Suregraft 0.25 Tablet suppresses the activity of body's immune system and prevents rejection of the transplanted organ.
Quick Tips
Suregraft 0.25 Tablet is given for the treatment of certain cancers and to prevent organ transplant rejection. It may affect male or female fertility; consult your doctor if you are planning to have a child. Inform your doctor straight away if you think you are getting a sore throat or if you have a high temperature. While you are taking Suregraft 0.25 Tablet do not take any vaccinations without talking to your doctor first. If you are having an operation or dental treatment, always tell the person carrying out the treatment that you are taking Suregraft 0.25 Tablet. Do not drink grapefruit juice while you are taking this medicine.
Related Medicines
Everomus 0.25mg Tablet
Certican 0.25mg Tablet
Everotas 0.25mg Tablet
Eversure 0.25 Tablet
Evercon 0.25mg Tablet
Evergraf 0.25mg Tablet
Advacan 0.25mg Tablet
Natlimus 0.25mg Tablet
Lanolimus 0.25mg Tablet
Frequently asked questions
What type of monitoring is required while taking Suregraft 0.25 Tablet? Is there any special blood test requirement for my treatment?
Regular blood tests are necessary when taking Suregraft 0.25 Tablet. These tests will measure red blood cell counts, white blood cell counts, and platelet counts. Additionally, the doctor may order blood tests to assess kidney function, liver function, blood glucose levels, and cholesterol levels.
What should I avoid while taking Suregraft 0.25 Tablet? Is there any medication or food interaction to be aware of?
Grapefruit or grapefruit juice should not be consumed alongside Suregraft 0.25 Tablet, as they can increase the levels of Suregraft 0.25 Tablet in your blood to potentially harmful levels. It's also essential to avoid live vaccinations and any potential contact with individuals who have received live vaccinations.
What is the most important information I need to know about Suregraft 0.25 Tablet? What are the possible risks and side effects?
Suregraft 0.25 Tablet can cause serious adverse reactions, including severe allergic reactions (anaphylaxis), angioedema (swelling of the face, lips, and tongue), and kidney failure that can be life-threatening. There is also a possibility of developing infections or lung problems like breathing difficulties.
What kind of medicine is Suregraft 0.25 Tablet?
Suregraft 0.25 Tablet is an anticancer medication belonging to the class of kinase inhibitors. It works by reducing blood supply to tumors, slowing the growth and spread of cancer cells.
How is Suregraft 0.25 Tablet administered?
Usually, Suregraft 0.25 Tablet is taken once or twice a day. The medication should be taken with food or without food. Always swallow the whole tablet with water and avoid crushing or chewing it.
What is the duration of taking Suregraft 0.25 Tablet?
There is no set timeframe for treatment with Suregraft 0.25 Tablet. The duration depends on the response to treatment, the severity of your cancer, and any side effects or complications.
How will I know if Suregraft 0.25 Tablet shrinks my brain tumor?
The size of your brain tumor can be assessed with regular brain scans as recommended by your doctor. These scans are crucial in determining the effectiveness and progress of your treatment plan.
Is Suregraft 0.25 Tablet cytotoxic? Are there any types of cancer that it specifically targets?
Yes, Suregraft 0.25 Tablet is cytotoxic to human cancer cells of breast, stomach, prostate, and kidneys (renal cell carcinoma). It works by inhibiting the activity of specific enzymes in these cancers.
